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BACKGROUND: To compare the success rate and cost-
effectiveness (from the perspective of the healthcare pro-
vider) of ciprofloxacin (C) and trimethoprim/sulfamethox-
azole (TMP/SMX) in the ambulatory treatment of women
with acute uncomplicated pyelonephritis (AUPN). 
METHODS: A randomized double-blind study was per-
formed on women presenting to the emergency room
with symptoms of AUPN. Treatment regimens consisted
of either: C (500 mg) twice daily or TMP/SMX (160 mg/
800 mg) twice daily. Duration of treatment was 14 days.
The data necessary to calculate success rates and direct
medical costs were collected.
RESULTS: A total of 89 patients were randomized and in-
cluded in the cost-effectiveness analysis. Thirty-six patients
(C:19; TMP/SMX:17) were excluded from the success rate
analysis for the following reasons: 2 due to renal abnor-
malities (C:11; TMP/SMX:1), 3 due to failed urine cultures
(C:12; TMP/SMX:1), 9 due to resistance to TMP/SMX
(C:5; TMP/SMX:4), 16 due to negative urine cultures (C:7;
TMP/SMX:9), and 6 due to loss to follow-up (C:4; TMP/
SMX:2). Fifty-three evaluable patients remained (C:26;
TMP/SMX:27). Treatment success was defined as a negative
urine culture and absence of symptoms at the time of the fol-
low-up visit. Overall success rate: C: 22 of 26; TMP/SMX:
16 of 27 (p  0.0405). Direct medical costs: C: $278.39;
TMP/SMX: $546.15 Canadian (p  0.0048).
CONCLUSION: Ciprofloxacin produces fewer side effects
and has a higher cure rate than trimethoprim/sulfamethox-
azole. As a result, and despite its higher acquisition cost,
ciprofloxacin is more cost-effective than trimethoprim/sul-
famethoxazole in the ambulatory treatment of AUPN in
women.
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PRELIMINARY QUALITY-OF-LIFE EVALUATION 
OF THE GERMAN SAT TRIAL: COMPARISON OF 
SF-36, EUROQOL, TIME TRADE-OFF METHOD, 
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Cologne, Germany
OBJECTIVE: To assess the effectiveness of an evidence-
based treatment of obesity in a primary care setting, we
conducted the SAT trial (Sibutramine in Adiposity Trial),
a multicenter, double-blind, placebo-controlled, random-
ized parallel group comparison of a 54 weeks continuous
therapy with Sibutramine 15 mg or placebo, in addition
to a standardized nonpharmacological therapy consisting
of a calorie-restricted diet, modification of eating behav-
ior and lifestyle, and an activity program. Patients with a
body mass index (BMI) of greater than 30 and less than
40 were included. The primary endpoint in this study is
weight loss in kilograms between the last measurement of
body weight (visit 11) and the measurement at the first
visit. Secondary endpoints are, amongst other clinical pa-
rameters, health economic and quality of life data.
METHODS: Quality of life is measured by four different
instruments: the Short Form 36 (SF-36), the EuroQol, the
time trade-off method (TTO), and the willingness to pay
method (WTP). The SF-36 is a general, standardized and
validated quality-of-life instrument, consisting of 36 ques-
tions that can be aggregated into eight health dimensions.
The EuroQol is also a general, standardized and vali-
dated quality-of-life questionnaire, having the advantage
of aggregating the five health dimensions into one quality-
of-life index. Therefore, the EuroQol is frequently used in
health economic evaluations to calculate quality-adjusted
life-years saved (QALYs). In the TTO interview, patients
are asked questions so that we may calculate a quality-of-
life index for each patient (stratified by age). In the will-
ingness to pay questionnaire, obese patients are asked
how much they would be prepared to pay per month for
an immediate and sustained weight loss of 10 kg from
their current body weight. The answers are stratified by
net income classes.
RESULTS: Quality of life measured by the SF-36 has im-
proved in all eight health dimensions at visit 2 compared
to visit 1. Social functioning is especially impaired in
obese patients. The quality-of-life index measured by the
EuroQol has slightly improved from visit 1 to visit 2 over
all age groups. The results of the quality-of-life index of
the TTO interview and the EuroQol questionnaire are
very similar except in the age group 35 years. Willing-
ness to pay correlates positively with net income.
DISCUSSION: The results reveal the massive burden of
obese patients.
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COST-EFFECTIVENESS OF TREATING HIGH-
RISK INDIVIDUALS, AGED 45–65, WITH STATINS 
IN GERMANY FOR PRIMARY AND SECONDARY 
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Lauterbach KW, Hunsche E, Klewer U
Institute for Health Economics and Clinical Epidemiology, 
University of Cologne, Cologne, Germany
Cost-effectiveness of primary and secondary prevention
of coronary heart disease in Germany was analyzed re-
